Faruqi & Faruqi Launches Investigation on Behalf of Tvardi Investors After Major Stock Drop

Investigation of Tvardi Therapeutics by Faruqi & Faruqi

Faruqi & Faruqi, LLP, known as a leading national securities law firm, has initiated an investigation aimed at uncovering claims on behalf of investors in Tvardi Therapeutics, Inc. The firm is particularly focused on investors who might have suffered considerable losses due to the recent downturn of Tvardi's stock after the release of disappointing clinical trial data.

On October 13, 2025, Tvardi Therapeutics' shares experienced a staggering drop of over 80%. This dramatic decline was triggered by the release of preliminary findings from the Phase 2 REVERT clinical trial concerning TTI-101, which is aimed at addressing idiopathic pulmonary fibrosis (IPF). The trial's primary objective was to evaluate the safety and efficacy of TTI-101, and its results fell far short of expectations.

The preliminary results indicated that the trial did not meet its predefined objectives, raising significant concerns among investors. It became evident that the safety and efficacy data could not support the anticipated claims for TTI-101. The initial losses have left many shareholders questioning their investments and seeking guidance on their options moving forward.

James (Josh) Wilson, a senior partner at Faruqi & Faruqi, expressed his commitment to assisting those who have incurred significant losses related to Tvardi’s stock. Shareholders and investors are being encouraged to reach out for discussions regarding their legal rights and potential claims. This proactive step aims to provide a voice to those who feel wronged by the company’s performance and the sudden shift in market perception.

The investigation by Faruqi & Faruqi hinges on a professional reputation that spans decades and is bolstered by the firm’s history of securing hundreds of millions in recoveries for investors since its establishment in 1995. With offices strategically located in New York, Pennsylvania, California, and Georgia, the firm is well-positioned to navigate the complexities of securities litigation and advocate for the rights of investors across the nation.

Investors interested in learning more about the ongoing investigation can visit Faruqi & Faruqi's official webpage or directly contact partner Josh Wilson. The firm stresses the confidential nature of all inquiries, aiming to create a supportive environment for affected investors who are analyzing their next steps post-investment loss.

Furthermore, the implications of this trial and the associated clinical data will likely resonate throughout the biotech community, affecting not only Tvardi but potentially illustrating broader market sentiments regarding risk management in therapeutic trials. As the story develops, stakeholders in the biotech sector are keeping a keen eye on outcomes that shape market confidence and investor positions.

In conclusion, Faruqi & Faruqi stands ready to extend its expertise in helping Tvardi’s investors navigate these trying times. With legal avenues being explored, shareholders are given a renewed hope to reclaim their positions in light of recent events.